Clinuvel Pharmaceuticals Limited (FRA:UR9A)
Germany flag Germany · Delayed Price · Currency is EUR
6.05
+0.15 (2.54%)
At close: Nov 26, 2025

Clinuvel Pharmaceuticals Ratios and Metrics

Millions EUR. Fiscal year is Jul - Jun.
Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 20212016 - 2020
Period Ending
Nov '25 Jun '25 Jun '24 Jun '23 Jun '22 Jun '21 2016 - 2020
337290479539484959
Upgrade
Market Cap Growth
-19.60%-39.41%-11.00%11.37%-49.58%23.36%
Upgrade
Enterprise Value
211180371454419914
Upgrade
Last Close Price
6.405.539.2310.709.4417.98
Upgrade
PE Ratio
16.6914.3821.6028.8735.1461.34
Upgrade
PS Ratio
6.355.488.7311.2811.1631.39
Upgrade
PB Ratio
2.512.163.795.375.8415.36
Upgrade
P/TBV Ratio
2.512.163.805.375.8515.39
Upgrade
P/FCF Ratio
14.7912.7524.4624.6218.6182.41
Upgrade
P/OCF Ratio
14.6912.6620.7723.9318.4078.75
Upgrade
EV/Sales Ratio
3.943.406.769.509.6829.91
Upgrade
EV/EBITDA Ratio
7.986.9412.0916.7117.6849.73
Upgrade
EV/EBIT Ratio
8.187.0512.2816.8617.8950.60
Upgrade
EV/FCF Ratio
9.267.9118.9520.7316.1378.52
Upgrade
Debt / Equity Ratio
0.000.000.000.010.010.01
Upgrade
Debt / EBITDA Ratio
0.010.010.020.020.030.04
Upgrade
Debt / FCF Ratio
0.010.010.030.030.030.07
Upgrade
Asset Turnover
0.380.380.420.460.520.51
Upgrade
Inventory Turnover
0.870.870.771.333.691.87
Upgrade
Quick Ratio
9.249.248.337.0210.0311.35
Upgrade
Current Ratio
9.669.668.817.4410.2411.81
Upgrade
Return on Equity (ROE)
16.30%16.30%19.39%21.09%18.62%28.95%
Upgrade
Return on Assets (ROA)
11.37%11.37%14.29%16.34%17.60%18.78%
Upgrade
Return on Capital (ROIC)
12.85%12.85%16.43%18.86%19.59%20.59%
Upgrade
Return on Capital Employed (ROCE)
18.70%18.70%23.60%26.20%27.30%28.60%
Upgrade
Earnings Yield
5.99%6.95%4.63%3.46%2.84%1.63%
Upgrade
FCF Yield
6.76%7.84%4.09%4.06%5.38%1.21%
Upgrade
Dividend Yield
0.37%0.51%0.34%0.29%0.28%0.09%
Upgrade
Payout Ratio
6.92%6.92%6.93%6.46%5.92%5.00%
Upgrade
Buyback Yield / Dilution
1.27%1.27%1.52%-0.08%-1.26%-1.33%
Upgrade
Total Shareholder Return
1.64%1.77%1.86%0.21%-0.98%-1.24%
Upgrade
Source: S&P Global Market Intelligence. Standard template. Financial Sources.